CA2509817C - Forming iron nitrosyl hemoglobin - Google Patents

Forming iron nitrosyl hemoglobin Download PDF

Info

Publication number
CA2509817C
CA2509817C CA2509817A CA2509817A CA2509817C CA 2509817 C CA2509817 C CA 2509817C CA 2509817 A CA2509817 A CA 2509817A CA 2509817 A CA2509817 A CA 2509817A CA 2509817 C CA2509817 C CA 2509817C
Authority
CA
Canada
Prior art keywords
hemoglobin
nitrite
blood
red blood
blood cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2509817A
Other languages
English (en)
French (fr)
Other versions
CA2509817A1 (en
Inventor
Jonathan S. Stamler
David J. Singel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University Bozeman
Duke University
Original Assignee
Montana State University Bozeman
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University Bozeman, Duke University filed Critical Montana State University Bozeman
Publication of CA2509817A1 publication Critical patent/CA2509817A1/en
Application granted granted Critical
Publication of CA2509817C publication Critical patent/CA2509817C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2509817A 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin Expired - Fee Related CA2509817C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43261602P 2002-12-12 2002-12-12
US60/432,616 2002-12-12
PCT/US2003/037081 WO2004054433A2 (en) 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin

Publications (2)

Publication Number Publication Date
CA2509817A1 CA2509817A1 (en) 2004-07-01
CA2509817C true CA2509817C (en) 2014-11-04

Family

ID=32595081

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2509817A Expired - Fee Related CA2509817C (en) 2002-12-12 2003-12-10 Forming iron nitrosyl hemoglobin

Country Status (6)

Country Link
US (1) US8075922B2 (https=)
EP (1) EP1575419B1 (https=)
JP (2) JP5305554B2 (https=)
AU (2) AU2003295697B2 (https=)
CA (1) CA2509817C (https=)
WO (1) WO2004054433A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2294543T3 (es) 2003-07-09 2008-04-01 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heal Uso de sales de nitrilo para el tratamiento de afecciones cardiovasculares.
AU2006220548B2 (en) 2005-03-07 2011-04-21 Sangart, Inc. Composition and methods for delivering carbon monoxide (CO) and nitric ozide (NO) CO to tissue using heme proteins as carriers
CN1325518C (zh) * 2005-09-09 2007-07-11 李勇 人细胞膜抗原的保存方法及磁性粒子包被人细胞膜抗原
DE102007026071A1 (de) * 2007-05-24 2008-11-27 Seereal Technologies S.A. Richtungsgesteuerte Beleuchtungseinheit für ein autostereoskopisches Display
WO2009029836A2 (en) * 2007-08-31 2009-03-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes
WO2009038796A1 (en) 2007-09-20 2009-03-26 Wake Forest University Health Sciences Methods of treatment for hemolysis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US6291424B1 (en) 1991-11-14 2001-09-18 Brigham And Women's Hospital Nitrosated and nitrosylated heme proteins
WO1996030006A1 (en) * 1995-03-24 1996-10-03 Brigham And Women's Hospital Nitrosylated blood substitutes
US6153186A (en) 1995-09-15 2000-11-28 Duke University Medical Center Red blood cells loaded with S-nitrosothiol and uses therefor
AT405135B (de) * 1997-01-17 1999-05-25 Immuno Ag Präparation umfassend thiolgruppen-hältige proteine
EP1015490B1 (en) 1997-02-06 2004-04-14 Duke University No-modified hemoglobins and uses therefor
US6087087A (en) 1997-07-03 2000-07-11 Takashi Yonetani Treatment of hemoglobin with nitric oxide
DE60043731D1 (de) * 1999-08-02 2010-03-11 Univ Duke Methode zur bestimmung der physiologischen wirkungen von hämoglobin
AU2003232019A1 (en) * 2002-05-29 2003-12-19 Duke University Measuring nitric oxide in blood gases and treatments based thereon

Also Published As

Publication number Publication date
AU2003295697A1 (en) 2004-07-09
JP2006514643A (ja) 2006-05-11
US20060252671A1 (en) 2006-11-09
WO2004054433A2 (en) 2004-07-01
WO2004054433A3 (en) 2005-09-09
JP2010120971A (ja) 2010-06-03
EP1575419A4 (en) 2009-11-11
CA2509817A1 (en) 2004-07-01
EP1575419B1 (en) 2015-05-27
AU2010201151B2 (en) 2012-12-13
AU2010201151A1 (en) 2010-04-15
US8075922B2 (en) 2011-12-13
JP5305554B2 (ja) 2013-10-02
AU2003295697A8 (en) 2004-07-09
AU2003295697B2 (en) 2009-12-24
EP1575419A2 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
AU2010201151B2 (en) Forming Iron Nitrosyl Hemoglobin
US6670323B1 (en) Reduced side-effect hemoglobin compositions
Alayash et al. Hemoglobin and free radicals: implications for the development of a safe blood substitute
Standl et al. Hemoglobin-based oxygen carrier HBOC-201 provides higher and faster increase in oxygen tension in skeletal muscle of anemic dogs than do stored red blood cells
HU211989A9 (en) Low affinity mutant hemoglobins and wholly artificial hemoglobins as blood substitutes
Gould et al. The development of hemoglobin solutions as red cell substitutes: hemoglobin solutions
ES2202535T3 (es) Hemoglobina provista de ligandos protectores de los sitios de union al oxigeno artificial para la aplicacion biologico-medica directa y procedimiento para su preparacion.
Keipert et al. Functional properties of a new crosslinked hemoglobin designed for use as a red cell substitute
US6114505A (en) Hemoglobin mutants that reduce heme loss
US5844090A (en) Modified hemoglobin-like compounds
US6160098A (en) Method for control of functionality during cross-linking of hemoglobins
EP3595702B1 (en) Modified haemoglobin proteins
US20150306183A1 (en) Five-coordinate neuroglobin and use thereof as a blood substitute
JP2004500871A (ja) 人工ヘモグロビン変異体、医薬組成物、プラスミド、人工ヘモグロビン変異体および人工ヒトヘモグロビン変異体、ならびに人工ヘモグロビンの製造方法
JP2002540081A (ja) ヘモグロビン−抗酸化剤複合体
JP2006514643A5 (https=)
JPH11506314A (ja) 低酸素親和性突然変異ヘモグロビン
US6812207B1 (en) Hemoglobin mutants that reduce heme loss
Lieberthal Renal effects of hemoglobin-based blood substitutes
US20250064942A1 (en) Artificial oxygen carrier blood product
Moore Emerging role of hemoglobin solutions in trauma care
Moss The Manufacture and Study of Hemoglobin-Saline Solution.
WO2006016560A1 (ja) 組換えヒト血清アルブミン－金属ポルフィリン錯体、人工酸素運搬体および赤血球代替物
Kumar et al. Biotechnological Riches

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161212